[Zai LAB (ZLAB US, SELL, TP US$20) TP Change]: Two Positive News Drove up 2024 Growth Target
⬇ $Zai Lab Ltd(ZLAB)$ - Positive news for Zai Lab's Efgartigimod as rival drug is withdrawn and it is included in 2024 NDRL, leading to an 8.8% increase in top line but no change in operating loss. TP raised to $20.
Continue reading on Smartkarma:- https://www.smartkarma.com/insights/zai-lab-zlab-us-sell-tp-us-20-tp-change-two-positive-news-drove-up-2024-growth-target?utm_source=tiger_community
By Eric Wen, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/eric-wen?utm_source=tiger_community
On Zai Lab Ltd (ZLAB):- https://www.smartkarma.com/entities/zai-lab-ltd?utm_source=tiger_community
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
